Measuring the relationship between employees' health risk factors and corporate pharmaceutical expenditures

Journal of Occupational and Environmental Medicine

Volumn 45, Issue 8, 2003, Pages 793-802

  Burton, Wayne N ^a   Chen, Chin Yu ^b   Conti, Daniel J ^a   Schultz, Alyssa B ^b   Edington, Dee W ^b  

^a Bank One   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG COST; EMPLOYEE; HEALTH CARE COST; HEALTH HAZARD; HEALTH SERVICE; HUMAN; PHARMACY; QUALITY OF LIFE; RISK FACTOR; SELF REPORT;

ADULT; CHICAGO; DRUG COSTS; EDUCATION, CONTINUING; EMPLOYER HEALTH COSTS; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH STATUS INDICATORS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LIFE STYLE; MALE; MIDDLE AGED; OCCUPATIONAL HEALTH; QUESTIONNAIRES; RISK FACTORS; UNITED STATES;

EID: 0042662708     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000079090.95532.db     Document Type: Article

References (41)

1. Hyner GC, Peterson KW, Travis JW, Dewey JE, Foerster JJ, Framer EM, eds. Introduction. SPM Handbook of Health Assessment Tools. Pittsburgh: Society of Prospective Medicine; 1999:XX-XXII.
2. Wetzler, H. The status of health status assessment. In: Hyner GC, Peterson KW, Travis JW, Dewey JE, Foerster JJ, Framer EM, eds. SPM Handbook of Health Assessment Tools. Pittsburgh: Society of Prospective Medicine; 1999:17-24.
3. Terry P, Anderson DR, Serxner S. Health assessment at the worksite. In: Hyner GC, Peterson KW, Travis JW, Dewey JE, Foerster JJ, Framer EM, eds. SPM Handbook of Health Assessment Tools. Pittsburgh: Society of Prospective Medicine; 1999:207-216.
4. Pelletier KR. A review and analysis of the health and cost-effective outcome studies of comprehensive health promotion and disease prevention programs in the worksite: 1991-1993 Update. Am J Health Promot. 1993;8:50-62.
5. Department of Health and Human Services, Public Health Service. 1992 National survey of worksite health promotion activities: Summary. Am J Health Promot. 1993;7:452-464.
6. Gebhardt DL, Crump CE. Employee fitness and wellness programs in the workplace. Am Psychol. 1990;45:262-271.
7. Warner K, Wickizer T, Wolfe R, Schildroth J, Samuelson M. Economic implications of workplace health promotion programs: review of the literature. J Occup Med. 1988;30:106-112.
8. Vickery D, Golaszewski T, Wright E, McPhee L. Lifestyle and organizational health insurance costs. J Occup Med. 1986;28:1165-1168.
9. Yen LTC, Edington DW, Witting P. Associations between employee health-related measures and prospective medical insurance costs in a manufacturing company. Am J Health Promot. 1991;6:46-54.
10. Brink S. Health Risks and Behavior: The Impact on Medical Costs. Brookfield, WI: Milliman & Robertson; 1987.
11. Golaszewski T, Lynch W, Clearie A, Vickery D. The relationship between retrospective health insurance claims and a health risk appraisal-generated measure of health status. J Occup Med. 1989;31:262-264.
12. Goetzel RZ, Anderson DR, Whitmore RW, et al. The relationship between modifiable health risks and health care expenditures: an analysis of the multi-employer HERO health risk and cost database. J Occup Environ Med. 1998;40:843-854.
13. Edington DW. Emerging research: a view from one research center. Am J Health Promot. 2001;15:341-349.
14. Musich SA, Adams L, Edington DW. Effectiveness of health promotion programs in moderating medical costs in the USA. Health Promot Int. 2000;15:5-15.
15. Yen L, Edington D, Witting P. Predictions of prospective medical claims and absenteeism costs for 1284 hourly workers from a manufacturing company. J Occup Med. 1992;34:428-435.
16. Bertera R. The effects of behavioral risks on absenteeism and health-care costs in the workplace. J Occup Med. 1991;33:1119-1124.
17. Wright DW, Marshall JB, Edington DW. Association of health risks with the cost of time away from work. J Occup Environ Med. 2002;44:1126-1134.
18. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The role of health risk factors and disease on worker productivity. J Occup Environ Med. 1999;41:863-887.
19. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The economic burden of lost productivity due to migraine headache: a specific worksite analysis. J Occup Envrion Med. 2002;44:523-529.
20. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405-418.
21. Cockburn IM, Bailit AL, Berndt ER, Finkelstein SN. Loss of work productivity due to illness and medical treatment. J Occup Environ Med. 1999;41:948-953.
22. Steinwachs DM. Pharmacy benefit plans and prescription drug spending. JAMA. 2002;288:1773-1774.
23. Levit K, Cowan C, Lazenby H, et al. Health spending in 1998: Signals of changes. Health Aff. 2000;19:124-132.
24. Levit K, Smith C, Cowan C, et al. Inflation spurs health spending in 2000. Health Aff. 2002;21:172-181.
25. Musich S, Adams L, DeWolf G, Edington DW. A case study of 10-year health risk appraisal participation patterns in a comprehensive health promotion program. Am J Health Promot. 2001;15:237-240.
26. Stein AD, Shakour SK, Zuidema RA. Financial incentives, participation in employer-sponsored health promotion, and changes in employee health and productivity: HealthPlus Health Quotient Program. J Occup Environ Med. 2000;42:1148-1155.
27. Centers for Disease Control and Prevention, U. S. Department of Health and Human Services, Fact Sheets. Facts about cardiovascular disease. Available at: http://www.cdc.gov/od/oc/media/fact/ cardiova.htm. Accessed December 26, 2002.
28. Daviglus ML, Liu K, Greenland P, et al. Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to medicare costs. N Engl J Med. 1998;339:1122-1129.
29. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors or cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med. 1998;158:655-662.
30. Rizzo JA, Abbott TA III, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ. 1996;3:249-265.
31. Elliott WJ. The costs of treating hypertension: what are the long-term realities of cost containment and pharmacoeconomics? Postgrad Med. 1996;4:241-252.
32. Roth MS, Davenport RC, Simpson W. Assessing the economic value of antihypertensive medications. Am J Manage Care. 1998;4:1267-1275.
33. Hay JW, Yu WM, Ashraf T, Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics. 1999;15:47-74.
34. Jacobson TA, Schein JR, Williamson A, Ballantyne CM. Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med. 1998;158:1977-1989.
35. Centers for Disease Control and Prevention, US Department of Health and Human Services. Medical care expenditures attributable to cigarette smoking - United States, 1993. MMWR. 1994:469-472.
36. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-1529.
37. Thompson DT, Edelsberg J, Colditz GA, Bird AP, Oster G. Lifetime health and economic consequences of obesity. Arch Intern Med. 1999;159:2177-2183.
38. Narbro K, Agren G, Jonsson E, Näslund I, Sjöström L, Peltonen M. Pharmaceutical costs in obese individuals. Arch Intern Med. 2002;162:2061-2069.
39. Bardel A, Wallander MA, Svärdsudd K. Reported current use of prescription drugs and some of its determinants among 35- to 65-year-old women in mid-Sweden: a population-based study. J Clin Epidemiol. 2000;53:637-643.
40. Burton WB, Chen C-Y, Schultz AB, Edington DW. The economic costs associated with body mass index in a workplace. J Occup Environ Med. 1998;40:786-792.
41. Barendregt JJ, Bonneux L, van der Maas PJ. The health costs of smoking. N Engl J Med. 1997;337:1052-1057.